Saturday 17 October 2026
Export BGMS’s income statement to Excel — free account
Bio Green Med Solution, Inc.
BGMS Healthcare Biotechnology
Bio Green Med Solution, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747,000.00, up 1,637.2% from fiscal 2024. In the quarter to June 2026, revenue grew 3,260.0%, EPS grew 91.8% and free cash flow grew 66.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.91
0.08
+9.64%
Follow BGMS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
76.19 | 4.25 | 3.56 | 2.74 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(21.77) | (98.00) | (19.64) | (14.47) | |
P/B ratio |
1.33 | 0.47 | 0.81 | 0.71 | |
Price to Tangible BV |
1.71 | 0.61 | 1.05 | 0.91 | |
EV/Sales |
45.24 | (0.36) | 1.38 | 0.70 | |
EV/EBITDA |
0.00 | 0.03 | 0.00 | 0.00 | |
EV/Operating CF |
(0.92) | 0.06 | (1.18) | (1.19) | |
EV/FCF |
(0.93) | 0.06 | (1.24) | (1.30) | |
Quick Ratio |
4.55 | 3.58 | 5.69 | 7.03 | |
Current Ratio |
6.43 | 4.70 | 7.06 | 8.63 | |
Net Debt/EBITDA |
3.87 | 1.78 | 13.63 | 9.07 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.12 | 0.27 | 0.30 | |
Operating CF/Net income |
0.17 | 0.00 | 1.28 | 0.83 | |
Capex/Depreciation |
0.00 | 0.00 | (1.00) | 0.00 | |
Research and Development Expense of Revenue |
6.17% | 126.58% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,239.51% | 187.69% | 50.00% | 147.92% | |
Intangible Assets out of Total Assets |
0.19 | 0.19 | 0.21 | 0.20 | |
Share Based Compensation of Revenue |
7.41% | 98.35% | 0.13% | 0.00% | |
Graham Net Nets |
0.57 | 1.52 | 0.88 | 1.04 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1,653.28%) | (319.04%) | (454.00%) | (400.00%) | |
Free Cash Flow Yield |
(63.54%) | (144.71%) | (31.25%) | (19.67%) | |
Revenue per Share |
0.04 | 0.30 | 0.14 | 0.06 | |
Operating CF per Share |
(0.23) | (0.02) | (0.05) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.23) | (0.02) | (0.05) | (0.06) | |
Cash per Share |
2.01 | 1.60 | 0.61 | 0.68 | |
Shareholders Equity per Share |
3.71 | 3.13 | 1.24 | 1.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.71 | 3.13 | 1.24 | 1.28 | |
Free Cash Flow |
(0.43) | (0.03) | (0.28) | (0.35) | |
Working Capital |
5.44 | 4.92 | 4.83 | 5.28 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
5.38 | 4.91 | 4.82 | 5.28 | |
EV/EBIT |
0.00 | 0.03 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.69 | 3.69 | 1.57 | 1.80 | |
Average Payables |
2.30 | 2.61 | 0.19 | 0.21 | |
Average Assets |
6.77 | 6.14 | 5.65 | 6.13 | |
Average Common Equity |
3.06 | 2.33 | 4.91 | 5.39 |
Columns are period end dates